Initial Statement of Beneficial Ownership (3)
April 10 2017 - 2:38PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Munsie Jeffrey A
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/31/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
MERRIMACK PHARMACEUTICALS INC [MACK]
|
(Last)
(First)
(Middle)
C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
General Counsel /
|
(Street)
CAMBRIDGE, MA 02139
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
(1)
|
5/3/2021
|
Common Stock
|
89518
|
$5.54
|
D
|
|
Stock Option (right to buy)
|
(1)
|
6/12/2022
|
Common Stock
|
10000
|
$6.80
|
D
|
|
Stock Option (right to buy)
|
(1)
|
8/22/2022
|
Common Stock
|
14100
|
$7.53
|
D
|
|
Stock Option (right to buy)
|
(1)
|
3/11/2023
|
Common Stock
|
32500
|
$6.35
|
D
|
|
Stock Option (right to buy)
|
(1)
|
2/10/2024
|
Common Stock
|
35000
|
$5.02
|
D
|
|
Stock Option (right to buy)
|
(2)
|
2/8/2025
|
Common Stock
|
30000
|
$9.08
|
D
|
|
Stock Option (right to buy)
|
(3)
|
2/7/2026
|
Common Stock
|
60000
|
$5.42
|
D
|
|
Explanation of Responses:
|
(1)
|
This option is fully vested.
|
(2)
|
This option vested as to 1/12th of the total number of shares on 5/9/15 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/9/18.
|
(3)
|
This option vested as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Munsie Jeffrey A
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE, MA 02139
|
|
|
General Counsel
|
|
Signatures
|
/s/ Brian J. Kickham, attorney-in-fact
|
|
4/10/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Apr 2024 to May 2024
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From May 2023 to May 2024